

COURSE FACULTY, IAS–USA STAFF, AND BOARD OF DIRECTORS

FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

EAST COAST VIRTUAL – JULY 14, 2020

Course Chairs	
Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University Atlanta, Georgia	<i>Dr. Lennox has received research funding to his institution from Bristol-Myers Squibb and ViiV Healthcare and served as a consultant to Gilead Sciences, Inc. (Updated 07/01/20)</i>
Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham, Alabama	<i>Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 3/12/20)</i>
Speakers	
Susan Buchbinder, MD Clinical Professor of Medicine and Epidemiology University of California San Francisco Director, Bridge HIV San Francisco Department of Public Health San Francisco, California	<i>Dr Buchbinder has participated in research trials that received provision of medicines from Gilead Sciences, Inc. (Updated 01/31/20)</i>
Rajesh T. Gandhi, MD Professor of Medicine Harvard University Boston, Massachusetts	<i>Dr Gandhi has served as a consultant or advisor to Merck & Co, Inc. (Updated 11/18/19)</i>
Jeanne M. Marrazzo, MD, MPH C. Glenn Cobbs, MD, Endowed Professor in Infectious Diseases University of Alabama at Birmingham Birmingham, Alabama	<i>Dr Marrazzo has received research grants from Merck & Co, Inc, and Cepheid; served as an advisor to Gilead Sciences, Inc, and BioFire Diagnostics, and served on a data safety monitoring board for Gilead Sciences, Inc. (Updated 09/02/19)</i>
IAS–USA CME Planner and Reviewer	
Donna M. Jacobsen Executive Director	<i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 02/06/19)</i>
Jeffrey L. Lennox, MD	<i>Dr. Lennox has received research funding to his institution from Bristol-Myers Squibb and ViiV Healthcare and served as a consultant to Gilead Sciences, Inc. (Updated 07/01/20)</i>
Michael S. Saag, MD	<i>Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 3/12/20)</i>
IAS–USA Board of Directors	
The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see https://iasusa.org/about/ias-usa-board-of-directors/ for information about board members and a link to up-to-date financial disclosure information.	